Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy
Tóm tắt
Patients with chronic hepatitis B (CHB) undergoing interferon (IFN)-α-based therapies often exhibit a poor HBeAg serological response. Thus, there is an unmet need for new therapies aimed at CHB. This study comprised two clinical trials, including 130 CHB patients, who were treatment-naïve; in the first, 92 patients were systematically analyzed ex vivo for interleukin-2 receptor (IL-2R) expression and inhibitory molecules expression after receiving Peg-IFN-α-2b therapy. In our second clinical trial, 38 non-responder patients, in whom IFN-α therapy had failed, were treated with or without low-dose IL-2 for 24 weeks. We then examined the hepatitis B virus (HBV)-specific CD8+T-cell response and the clinical outcome, in these patients. Although the majority of the participants undergoing Peg-IFN-α-2b therapy were non-responders, we observed a decrease in CD25 expression on their CD4+T cells, suggesting that IFN-α therapy may provide a rationale for sequential IL-2 treatment without increasing regulatory T cells (Tregs). Following sequential therapy with IL-2, we demonstrated that the non-responders experienced a decrease in the numbers of Tregs and programmed cell death protein 1 (PD-1) expression. In addition, sequential IL-2 administration rescued effective immune function, involving signal transducer and activator of transcription 1 (STAT1) activation. Importantly, IL-2 therapy significantly increased the frequency and function of HBV-specific CD8+T cells, which translated into improved clinical outcomes, including HBeAg seroconversion, among the non-responder CHB patients. Our findings suggest that sequential IL-2 therapy shows efficacy in rescuing immune function in non-responder patients with refractory CHB.
Từ khóa
Tài liệu tham khảo
Razavi-Shearer, D. et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3, 383–403 (2018).
Bertoletti, A. & Wang, F. S. Overview of the special issue on HBV immunity. Cell. Mol. Immunol. 12, 253–254 (2015).
Wang Y. et al. SAMD4 family members suppress human hepatitis B virus by directly binding to the Smaug recognition region of viral RNA. Cell. Mol. Immunol. 18, 1032–1044 (2020).
Cornberg, M., Lok, A. S., Terrault, N. A. & Zoulim, F. Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡). J. Hepatol. 72, 539–557 (2020).
Li, J. et al. Exosomes mediate the cell-to-cell transmission of IFN-[alpha]-induced antiviral activity. Nat. Immunol. 14, 793–803 (2013).
Rehermann, B. & Bertoletti, A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 61, 712–721 (2015).
Tan, A. T. et al. Reduction of HBV replication prolongs the early immunological response to IFNα therapy. J. Hepatol. 60, 54–61 (2014).
Rijckborst, V. & Janssen, H. L. The role of interferon in hepatitis B therapy. Curr. Hepat. Rep. 9, 231–238 (2010).
Rehermann, B. & Thimme, R. Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. Gastroenterology 156, 369–383 (2019).
Lazear, H. M., Schoggins, J. W. & Diamond, M. S. Shared and distinct functions of type I and type III interferons. Immunity 50, 907–923 (2019).
Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975–982 (2002).
Levrero, M., Subic, M., Villeret, F. & Zoulim, F. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Curr. Opin. Virol. 30, 80–89 (2018).
Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207 (2013).
Fu, B. et al. Immunomodulation induced during interferon-α therapy impairs the anti-HBV immune response through CD24(+)CD38(hi) B cells. Front. Immunol. 11, 591269 (2020).
Yuan W. et al. Peg IFN-ɑ treatment enhanced the inhibitory effect of NK cells on the differentiation and proliferation of CD4+CD25+ Tregs via IFN-γ in chronic hepatitis B. J. Infect. Dis. jiab216, https://doi.org/10.1093/infdis/jiab216. (2021).
Jung, M. K. & Shin, E. C. Regulatory T cells in hepatitis B and C virus infections. Immune Netw. 16, 330–336 (2016).
Bengsch, B., Martin, B. & Thimme, R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 61, 1212–1219 (2014).
Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Investig. 128, 4573–4587 (2018).
Fisicaro, P. et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat. Med. 23, 327–336 (2017).
Mullard, A. Restoring IL-2 to its cancer immunotherapy glory. Nat. Rev. Drug Discov. 20, 163–165 (2021).
Naito, S. et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 57, 317–326 (2010).
Saxena, S., Nouri-Aria, K., Anderson, M., Williams, R. & Eddleston, A. In vitro α-interferon treatment of peripheral blood mononuclear cells improves interleukin-2 activity in HBV-related chronic liver disease. J. Hepatol. 1, 385–393 (1985).
He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991–993 (2016).
Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17, 1322–1333 (2016).
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142–1151 (2005).
Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6, 345–352 (2005).
Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018).
Busse, D. et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc. Natl Acad. Sci. USA 107, 3058–3063 (2010).
Lau, G. K. et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682–2695 (2005).
Liao, W., Lin, J.-X., Wang, L., Li, P. & Leonard, W. J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12, 551–559 (2011).
Siegel, J. P., Sharon, M., Smith, P. L. & Leonard, W. J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 238, 75–78 (1987).
Malek, T. R. & Castro, I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153–165 (2010).
Kakumu, S. et al. Pilot study of recombinant human interleukin 2 for chronic type B hepatitis. Hepatology 8, 487–492 (1988).
Blattman, J. N. et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9, 540–547 (2003).
Bach, N., Schaffner, F. & Lin, S.-C. High-dose recombinant interleukin-2 for chronic viral hepatitis. Lancet 334, 281 (1989).
Bruch, H. R. et al. Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2. J. Hepatol. 17, S52–S55 (1993).
Tang, X. et al. Sustained IFN-I stimulation impairs MAIT cell responses to bacteria by inducing IL-10 during chronic HIV-1 infection. Sci. Adv. 6, eaaz0374 (2020).
Stegmann, K. A. et al. Interferon α–stimulated natural killer cells from patients with acute Hepatitis C Virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J. Infect. Dis. 205, 1351–1362 (2012).
Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513–545 (2014).
Li, P. et al. STAT5-mediated chromatin interactions in superenhancers activate IL-2 highly inducible genes: functional dissection of the Il2ra gene locus. Proc. Natl Acad. Sci. USA 114, 12111–12119 (2017).
Rivino, L. et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J. Clin. Investig. 128, 668–681 (2018).
Maini, M. K. et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117, 1386–1396 (1999).
Urbani, S. et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 41, 826–831 (2005).
Urbani, S. et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 76, 12423–12434 (2002).
Cheng Y. et al. Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection. Sci. Immunol. 4 eaau6905 (2019).
Wu, Y. et al. Frequencies of epitope-specific cytotoxic T lymphocytes in active chronic viral hepatitis B infection by using MHC class I peptide tetramers. Immunol. Lett. 92, 253–258 (2004).
Schuch, A. et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut 68, 905–915 (2019).
Dong, S. F. et al. Specific immune response to HBsAg is enhanced by beta-glucan oligosaccharide containing an alpha-(1–>3)-linked bond and biased towards M2/Th2. Int. Immunopharmacol. 7, 725–733 (2007).
Merino, A. et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J. Clin. Investig. 129, 3770–3785 (2019).
Li, H. et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. Gut 67, 2035–2044 (2018).
Wang, X. et al. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. Int. J. Infect. Dis. 99, 171–178 (2020).
Wing, J. B., Tanaka, A. & Sakaguchi, S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity 50, 302–316 (2019).
Lok, A. S. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63, 284–306 (2016).
Huang, R., Hao, Y., Zhang, J. & Wu, C. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: a meta-analysis. Hepatol. Res. 43, 1040–1051 (2013).
Yao, G. et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol. Int. 2, 486–493 (2008).
Seto, W. K. et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut 70, 775–783 (2021).